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PRPS1 Mutations:
Four Distinct Syndromes and Potential Treatment
Arjan P.M. de Brouwer,1,* Hans van Bokhoven,1,2 Sander B. Nabuurs,3 Willem Frans Arts,4
John Christodoulou,5,6 and John Duley7,8Phosphoribosylpyrophosphate synthetases (PRSs) catalyze the
ﬁrst step of nucleotide synthesis. Nucleotides are central to cell
function, being the building blocks of nucleic acids and serving
as cofactors in cellular signaling and metabolism. With this
in mind, it is remarkable that mutations in phosphoribosylpyrophos-
phate synthetase 1 (PRPS1), which is the most ubiquitously
expressed gene of the three PRS genes, are compatible with life.
Mutations described thus far in PRPS1 are all missense mutations
that result in PRS-I superactivity or in variable levels of decreased
activity, resulting in X-linked Charcot-Marie-Tooth disease-5
(CMTX5), Arts syndrome, and X-linked nonsyndromic sensori-
neural deafness (DFN2). Patients with PRS-I superactivity pri-
marily present with uric acid overproduction, mental retardation,
ataxia, hypotonia, and hearing impairment. Postlingual progres-
sive hearing loss is found as an isolated feature in DFN2 patients.
Patients with CMTX5 and Arts syndrome have peripheral neuro-
pathy, including hearing impairment and optic atrophy. However,
patients with Arts syndrome are more severely affected because
they also have central neuropathy and an impaired immune
system. The neurological phenotype in all four PRPS1-related
disorders seems to result primarily from reduced levels of GTP
and possibly other purine nucleotides including ATP, suggesting
that these disorders belong to the same disease spectrum. Prelim-
inary results of S-adenosylmethionine (SAM) supplementation in
two Arts syndrome patients show improvement of their condition,
indicating that SAM supplementation in the diet could alleviate
some of the symptoms of patients with PRPS1 spectrum diseases
by replenishing purine nucleotides (J.C., unpublished data).Introduction
Missense mutations in phosphoribosylpyrophosphate synthe-
tase 1 (PRPS1) (MIM 311850) result in four syndromes:
PRS-I superactivity (MIM 300661),1 Charcot-Marie-Tooth
disease-5 (CMTX5, or Rosenberg-Chutorian syndrome)
(MIM 311070),2,3 Arts syndrome (MIM 301835),4,5 and
X-linked nonsyndromic sensorineural deafness (DFN2)
(MIM 304500).6 PRPS1 belongs to a family that consists
of three very similar and highly conserved genes: PRPS1,
PRPS2 (MIM 311860), and PRPS1L1 (MIM 611566). In
contrast to PRPS1, PRPS2 and PRPS1L1 have not been
implicated in disease. PRPS1 codes for PRS-I, which cata-
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tial for the de novo synthesis of purine,8 pyrimidine,9
and pyridine nucleotides.10 Thus, mutations in PRPS1
affect vital cell functions, such as nucleic acid synthesis,
energy metabolism, and cellular signaling.
For purine synthesis, PRPP is utilized as a substrate for
PRPP amidotransferase (PPAT), which is the ﬁrst step in
the de novo purine synthesis pathway, producing purine
nucleotides such as ATP and GTP, and which serves specif-
ically as the rate-limiting reaction for purine nucleotide
synthesis in vivo.11 PRPP is also essential for pyrimidine
nucleotide synthesis, where it acts as cofactor for uridine
monophosphate synthetase (UMPS), which converts
orotic acid into UMP,9 the precursor of all other pyrimidine
nucleotides. Finally, PRPP is utilized for pyridine nucleo-
tide synthesis by nicotinate phosphoribosyl transferase
(NAPRT) and nicotinamide phosphoribosyl transferase
(NAMPT) to add a ribonucleotide moiety to nicotinic
acid and nicotinamide, respectively, which in turn are
converted into the important cofactors nicotinamide
adenine dinucleotide (NAD) and nicotinamide adenine
dinucleotide phosphate (NADP).10
Apart from de novo synthesis of purine, pyrimidine, and
pyridine nucleotides, PRPP is also used for the salvage of
purine bases by hypoxanthine guanine phosphoribosyl
transferase (HGPRT) and adenine phosphoribosyl trans-
ferase (APRT). This mechanism ensures efﬁcient reutiliza-
tion of purine bases and nucleosides, because de novo
purine nucleotide synthesis with PRPP as the substrate
requires in total seven moles of ATP for generation of
each mole of nucleotide, whereas salvage requires only
one mole of ATP for the synthesis of PRPP.12
The enzymatic activity of PRS-I is regulated by cofactors,
metabolites, and interacting proteins. Inorganic phos-
phate regulates enzyme activity by allosteric competition
with adenosine diphosphate, which is an inhibitor of
enzyme activity.13,14 In addition, inorganic phosphate
promotes the accessibility of the active site by stabilizing
a ﬂexible loop involved in ATP binding.15 Bivalent
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b- and g-phosphates of ATP, forming a Mg-ATP complex
that is the actual substrate of the enzyme.13,16 In addition,
the activity of PRS-I is regulated by its interaction with
PRS-II, 39 kDa phosphoribosylpyrophosphate synthetase-
associated protein (PAP39), and 41 kDa phosphoribosyl-
pyrophosphate synthetase-associated protein (PAP41).
Removal of the two PAP proteins from the PRS complex
results in increased PRS enzyme activity,17 which suggests
a negative regulatory role for these proteins, most likely by
sequestration of PRPP synthetases.18
PRPS1 transcript levels are controlled by miR-376.
miRNAs are ~21-nucleotide-long transacting RNA mole-
cules that repress activity of genes at the mRNA level by
complementary base pairing, thereby inhibiting protein
synthesis or causing mRNA degradation.19 The transcript
of PRPS1 contains two binding sites for the edited version
of miR-376 within 600 bp from the termination codon.20
These binding sites are not present in the 30 untranslated
region of PRPS2. The miR-376 cluster of miRNA genes
maps to chromosome 14q32.3121 and is expressed in mul-
tiple tissues during embryonic development and in adult
brain, heart, pancreas, and kidney.20,22 All of the cluster
members are transcribed into one long primary RNA tran-
script that can be subject to extensive and simultaneous
editing by adenosine deaminase at one or two speciﬁc
sites20 during the processing of primary transcripts to
mature miRNA.23–25 This editing is tissue speciﬁc for
miR-376. In the brain cortex most transcripts are edited,
whereas in the liver almost no editing occurs. Because
only the edited miR-376 silences the expression of PRPS1,
PRS-I activity is regulated by miR-376 in the cortex, but
not in the liver.20 Notably, patients with PRS-I superac-
tivity or impaired activity display neurological symptoms
such as ataxia and mental retardation, whereas the liver
functions normally.2,5,26 Taken together, these data indi-
cate that the activity of PRS-I is normally tightly regulated
in neuronal cells and that imbalances in nucleotide metab-
olism are particularly detrimental to neuronal function.
PRPS-1 Related Disorders
PRS-I Superactivity
PRS-I superactivity was ﬁrst described by Sperling et al. in
19721 as an X-linked disorder associated with excessive
uric acid production and gout. Since then, it has become
clear that inherited PRS-I superactivity results in a vari-
able clinical presentation characterized by early adult
onset of purine overproduction that causes hyperuricemia
and hyperuricosuria (Table 1)27,28 accompanied in some
kindreds by neurological problems, most notably mental
retardation, hypotonia, and sensorineural deafness.29–31
In one family, progressive axonal neuropathy with demye-
lination has been described.32
PRS-I superactivity can be caused by two different
mechanisms: (1) point mutations in the open reading
frame (ORF) of PRPS1 that result in regulatory defects
(Table 2),28,29,33–35 and (2) increased expression of PRS-I
that has normal kinetic enzyme properties.36–41 In total,The Amthere are more than 30 patients reported with PRS-I super-
activity.42 In seven of these, a point mutation in PRPS1 has
been identiﬁed.
(1) The severe PRS-I superactivity phenotypeswith purine
overproduction accompanied by neuropathy arise from
PRPS1ORF pointmutations. These result in impaired nucle-
otide feedback inhibition and inorganic phosphate activa-
tion. In this respect, the enzyme is not truly ‘‘superactive’’
because it does not have a higher Vmax than the normal
protein, but rather it lacks regulatory control of its activity,33
suggesting that these mutations can be considered as gain-
of-function mutations. Accordingly, PRS activity and PRPP
levels have been shown to be higher in ﬁbroblasts and
lymphoblasts of patients with PRPS1 ORF muta-
tions.28,32,34,43 Remarkably, in erythrocytes—where PRS-I
is the only PRS isoform present5—enzyme activity has
been found to be completely absent, accompanied by
reduced nucleotide levels, in particular low GTP and
NAD.31,32,43 This suggests that the mutated protein may be
more labile in postmitotic cells, such as erythrocytes and
brain cells, whereas itmay continue to overproduce purines
in dividing tissues such as skin ﬁbroblasts and liver.35 The
latter is, perhaps not coincidently, together with the small
intestine, the primary uric acid-producing tissue.44
(2) Increased expression of PRS-I accounts for the milder
phenotypes that manifest as purine overproduction
without any neuropathy. These patients have increased
PRPS1 transcript levels, but no genetic defects have been
identiﬁed in the ORF, the untranslated regions, or in 3 kb
of the promoter region.40,41,45 In addition, PRPS1 was not
duplicated.40 The overexpression has been shown to be
accompanied by raised intracellular levels of PRPP in all
cell types examined, i.e., ﬁbroblasts, lymphoblasts, and
erythrocytes.36–39 This does not result in raised nucleotide
levels, but instead the increased de novo purine synthesis
causes accelerated nucleotide degradation to uric acid.26
Because the kinetic properties of PRS-I in these patients
is not affected, the superactivity may be caused by changes
in a pretranslational mechanism of PRPS1 gene expression
through miR-376-regulated changes in PRPS1 transcript
levels. Theoretically, mutations in the miR-376 binding
sites of PRPS1 or inmiR-376 itself may result in PRS-I super-
activity. However, no binding site mutations have been
identiﬁed to date,41miR-376 itself has not been sequenced,
and the seven patients reported with PRPS1 overexpression
were male, whereas autosomal miR-376 involvement
would predict males and females to be equally affected.
Arts Syndrome
Arts syndrome is an X-linked disorder characterized by
mental retardation, early-onset hypotonia, ataxia, delayed
motor development, profound congenital sensorineural
hearing impairment, and optic atrophy (Table 1).4,5 In
males, liability to infections, especially of the upper respi-
ratory tract, almost invariably has resulted in an early
death before the age of ﬁve years in the original Arts
syndrome family. Obligate carrier females may showerican Journal of Human Genetics 86, 506–518, April 9, 2010 507
Table 1. General Clinical Description of Purine and Pyrimidine Disorders in Which PRPP Is Involved as Substrate and AHCY Deficiency
Clinical Symptom
PRS-I
Superactivity
Arts
Syndrome CMTX5 DFN2
HGPRT
Deficiency
APRT
Deficiency
UMPS
Deficiency
AHCY
Deficiency
Neurological
Mental retardation 5 þ   5   þ
Ataxia 5 þ þ     
Hypotonia 5 þ þ  5   þ
Delayed motor
development
5 þ   þ   þ
Areﬂexia 5 þ      
Loss of deep tendon
reﬂexes
 þ þ     þ
Hearing impairment 5 þ þ þ    
Optic atrophy  þ þ     
Uric acid overproduction
Gout þ    þ   
Kidney stones þ    5 þ*  
Renal failure þ     þ*  
Hematopoietic
Recurrent infections  þ     þ 
Anemia     5  þ 
Other
Short stature     5   
Self injury     5   
Early death  þ   5  5 
* The urolithiasis and renal failure in APRT deficiency are not caused by increased uric acid production but by accumulation of 2,8 dihydroxy-adenine.isolated and milder manifestations of symptoms, such as
perceptive hearing impairment, ataxia, hypotonia, and
hyperreﬂexia.4 Indeed, there was no skewing of X inactiva-
tion in the carrier females (A.P.M.d.B., unpublished data),
although PRPS1 is clearly subject to X inactivation.46
Linkage analysis in the Arts syndrome families suggested
that the causative genetic defect mapped to Xq22.1-q24.47
Whole-genome expression proﬁling of ﬁbroblasts from
two probands of the Dutch family revealed a nonsigniﬁ-
cant 1.8-fold reduction in PRPS1 RNA transcript levels.5
Subsequent sequencing of PRPS1 led to the identiﬁcation
of two missense mutations, c.455T>C (p.L152P) in the
original Dutch Arts syndrome kindred and c.398A>C
(p.Q133P) in an Australian family. PRPS1 expression
in the Australian family was found to be normal. Both
mutations result in a loss of PRS-I activity, as demonstrated
by in vitro PRS enzyme assays in erythrocytes and ﬁbro-
blasts from the Australian family and ﬁbroblasts from the
Dutch kindred. This was conﬁrmed by undetectable urine
hypoxanthine and reduced plasma uric acid levels in the
two patients from the Australian family.5
A sural nerve biopsy from an affected boy of the Austra-
lian family with Arts syndrome showed mild paranodal508 The American Journal of Human Genetics 86, 506–518, April 9, 2demyelination, indicative of peripheral neuropathy.5 In
addition, the central nervous system can be affected, as
shown by the complete absence of myelin in the posterior
columnsof the spinal cord in theonlypatient from theorig-
inal Arts syndrome kindredwhowas examined at autopsy.4
Conversely,MRI of the brains in the affected brothers in the
Australian family showed no recognizable abnormalities,
such as a reduction of white matter, which is indicative of
demyelination.5 Taken together, these observations suggest
that the demyelination is more apparent in the periphery
than in the central nervous system.
CMTX5, or Rosenberg-Chutorian Syndrome
CMTX5, or Rosenberg-Chutorian syndrome, is deﬁned by
peripheral neuropathy, early-onset sensorineural hearing
impairment, and optic neuropathy (Table 1).2,3 Hypotonia,
gait disturbances, and loss of deep tendon reﬂexes with an
onset from the age of 10 to 12 years have also been
reported. Peripheral demyelination and axonal loss seem
to be at the root of these late onset problems, as demon-
strated in the oldest living patient by a sural nerve biopsy.2
In contrast to Arts syndrome, mental retardation and
recurrent infections are not features of CMTX5.010
Table 2. Mutations Identified in PRPS1 in the Four Different
PRPS1-Related Disorders
Disorder
DNA
Mutation
Protein
Change
Functional
Change Reference
PRS-I
superactivity
154G>C D52H Gain of function Becker et al.35
341A>G N114S Gain of function Roessler et al.93
385C>A L129I Gain of function Becker et al.35
547G>C D182H Gain of function Roessler et al.93
569C>T A189V Gain of function Becker et al.35
578A>T H192L Gain of function Garcia-Pavia et al.94
579C>G H192Q Gain of function Becker et al.35
Arts
syndrome
398A>C Q133P Loss of function de Brouwer et al.5
455T>C L152P Loss of function de Brouwer et al.5
CMTX5 129A>C E43D Loss of function Kim et al.2
344T>C M115T Loss of function Kim et al.2
DFN2 193G>A D65N Loss of function Liu et al.6
259G>A A87T Loss of function Liu et al.6
869T>C I290T Loss of function Liu et al.6
916G>A G306R Loss of function Liu et al.6
In addition to a gain or loss of function, all mutations result in an unstable PRS-I
protein. Depending on the cell type, gain-of-function mutations can then
result in overactivity in actively dividing cells through loss of self-regulation
or in a loss of activity in postmitotic cells, explaining the complete absence
of activity in erythrocytes of patients with PRS-I superactivity.CMTX5 was mapped in a Korean kindred to Xq21.31-
q24.48 Analysis of 71 genes in the linkage interval revealed
a c.344T>C mutation in PRPS1, which leads to the substi-
tution of a threonine for a methionine residue at position
115 of PRS-I. PRS activity was decreased in ﬁbroblasts from
patients with this mutation.2 Subsequently, in a family
with Rosenberg-Chutorian syndrome, a transversion of
c.129A>C was identiﬁed that results in the substitution
of an aspartic acid for a glutamic acid residue at position
43 of PRS-I. Serum uric acid levels in patients with either
mutation were normal.2
DFN2
Patients with DFN2 have postlingual progressive nonsyn-
dromic hearing loss,6,49,50 although in one family congen-
ital profound nonsyndromic hearing loss was reported.51
Linkage analysis in a large Chinese family ﬁne-mapped
the DNF2 locus to Xq22.1-Xq23, which contains 119
genes.6 Subsequent DNA sequence analysis of the seven
exons of PRPS1 showed a transition of c.193G>A in exon
2 that results in the substitution of an aspartic acid for an
asparagine at amino acid residue position 65. The PRS-I
activity in erythrocytes and ﬁbroblasts was found to be
half, compared to unaffected males in the family. In
the other three DFN2 families, c.259G>A (p.A87T),
c.869T>C (p.I290T), and c.916G>A (p.G306R) mutations
were identiﬁed in PRPS1.6The AmEffect of the Disease-Causing Mutations
on the Structure of PRS-I
The physiologically active PRS unit is a hexamer that
consists of three homodimers arranged in a propeller-like
shape (Figure 1A), each with an active site and two regula-
tory allosteric sites, I and II.15,52 The active site comprises
binding sites for both ATP and ribose-5-phosphate and is
located at the interface of two domains within one homo-
dimer. Allosteric site I is located at the interface of the three
homodimers of a hexamer, and allosteric site II is at the
interface of two monomers within one homodimer.15,53
Mutations that Cause PRS-I Superactivity
Two of the amino acid residues’ substitutions, p.D52H and
p.L129I, which result in PRS-I superactivity, disturb the
local structure near one of the two allosteric sites,
hindering feedback inhibition. The p.D52H substitution
results in disruption of the hydrogen bonds in which the
Asp52 side chain is engaged (Figure 1B), which is predicted
to destabilize the local structure around Asp52, disturbing
allosteric site I. Leu129 is in the vicinity of allosteric site II,
where the leucine-to-isoleucine change results inmoderate
steric hindrance of the isoleucine side chain with both the
protein backbone at Ala131 and the side chain of Ile134
(Figure 1D). This is predicted to destabilize the local
structure around both of these amino acids and hence
disrupts allosteric site II.
The other substitutions described that cause PRS-I super-
activity, p.N114S, p.A190V, p.D183H, p.H193L, and
p.H193Q are all located in the homodimer interface.
Asn114 is located in an a helix and interacts with the
second monomer via a hydrogen bond with Asp139 (Fig-
ure 1C). The p.N114S change is predicted to break this
hydrogen bond and destabilize the homodimer. In addi-
tion, the Asn114 interaction with Val118 in the trimer
interface is also impaired by the p.N114S change. Ala190
is located in the center of a b sheet that plays a prominent
role near the top of the homodimer interface (Figure 1F).
The p.A190V change results in the substitution of the
small alanine side chain by a more bulky valine side chain,
which is predicted to disturb the tight hydrophobic pack-
ing environment in the homodimer interface. Asp183
and His193 are both located in the upper region of the
dimer interface (Figures 1E and 1G). The PRS-I crystal struc-
ture shows that Asp183 of one PRS-I subunit is involved in
a hydrogen bond to His193 of the adjacent PRS-1 subunit
in the homodimer. The p.D183H and p.H193L/Q substitu-
tions break this interaction, resulting in a destabilization of
the homodimer interface. Destabilization of the homo-
dimer is likely to disturb both PRS-I allosteric sites, because
these consist of amino acids originating from either two
(allosteric site II) or three (allosteric site I) PRS-I molecules.
Based on its central location in the dimer, we predict
allosteric site II to be the foremost site affected by the
above changes that disturb the homodimer interface. The
disturbance of allosteric site II would consequently result
in loss of feedback inhibition and in higher PRS enzymeerican Journal of Human Genetics 86, 506–518, April 9, 2010 509
Figure 1. Three-Dimensional Model of PRS-I as a Hexamer and a Close-Up of the Regions that Contain the Amino Acid Substitutions
(A) Three-dimensional model of PRS-I as a hexamer, with the six monomers labeled with different colors.
(B–G) Seven substitutions that result in PRS-I superactivity: p.D52H (B), p.N114S (C), p.L129I (D), p.D183H (E), p.A190V (F), and
p.H193L (G). Note that pH193Q has a similar effect on the PRS-I structure as p.H193L.
(H–K) Four substitutions that cause Arts syndrome and CMTX5: p.Q133P (H), p.L152P (I), p.E43D (J), and p.M115T (K).
(L–O) Four substitutions that result in DFN2: p.D65N (L), p.A87T (M), p.I290T (N), and p.G306R (O). All substitutions are shown for
monomer 1. Homodimer interactions are shown between monomer 1 (blue) and monomer 2 (cyan). Trimer interactions are shown
betweenmonomer 1, monomer 2, andmonomer 6 (purple). Hydrogen bonds are indicated with yellow dashed lines. Strong interatomic
steric hindrance is indicated with orange dashed arrows. The effect of PRPS1mutations on the structure of PRS-I was examined with the
crystal structures of the human protein from Li et al.15 The altered amino acid side chains in themodel were positioned with a backbone-
dependent rotamer library, as implemented in the YASARA program.activity, as seen in ﬁbroblasts and lymphoblasts.28,32,34,43
Moreover, decreased stability of the PRS unit could then
result in a gradual loss of enzyme activity, which could510 The American Journal of Human Genetics 86, 506–518, April 9, 2explain the absence of activity observed in postmitotic
cells such as erythrocytes and presumably brain
cells.31,32,43010
Mutations that Cause Arts Syndrome
PRS-I loss of activity observed in Arts syndrome has been
associated with p.Q133P and p.L152P. Gln133 is posi-
tioned in the homodimer interface and forms a hydrogen
bond to Asp98 from the second subunit in the homodimer
(Figure 1H). The p.Q133P change is predicted to disrupt
two intermolecular hydrogen bonds in the dimer interface,
destabilizing both the homodimer and the nearby allo-
steric site II. In addition, Gln133 and especially its
hydrogen-bonding partner Asp98 are in very close prox-
imity to the ATP-binding pocket. The amino acid residues
neighboring Asp98, namely Arg96, Gln97, Lys99, and
Asp101, all interact with the incoming ATP molecule.
Loss of the hydrogen bonding capacity at position 98 is
predicted to destabilize the ATP-binding pocket and thus
impair PRS-I activity. Leu152 is positioned in the middle
of one of the a helixes (Figure 1I). Replacement of this
leucine with a proline breaks the a-helical conﬁguration
and may consequently result in severe local distortion of
the tertiary structure. Leu152 is positioned directly above
Glu148, which interacts in the homodimer interface
with Lys102, originating from the other monomer. The
p.L152P substitution introduces interatomic interference
with the backbone of Glu148, which is predicted to
severely destabilize the local structure. This probably also
affects both Lys102 and the adjacent Tyr146, which both
participate in allosteric site II. Because Lys102 neighbors
the above-mentioned ATP-binding domain, ranging from
Arg96 to Asp101, the p.L152P substitution is predicted to
impair PRS-I activity.
Mutations that Cause CMTX5
The two amino acid residue changes that result in PRS-I
loss of function in patients with CMTX5 are both involved
in the PRS-I trimer interface. Glu43 is located in the so-
called ﬂag region (residues Val30–Ile44) and interacts via
a hydrogen bond with Ser103 located in the adjacent
dimer in the PRS-I hexamer (Figure 1J). The p.E43D change
is predicted to alter the way the ﬂag region interacts with
the adjacent PRS-I homodimer. Because this region of the
structure plays a critical role in ATP binding by the com-
plete hexamer, the substitution should result in decreased
synthetase activity. Met115 is also positioned in the trimer
interface (Figure 1K). Two Met115 side chains originating
from two different PRS-I dimers interact intimately in the
hydrophobic trimer interface. Rearrangement of the side
chains in the p.M115T substitution is predicted to disturb
the hydrophobic packing in the trimer interface, destabi-
lizing the ATP-binding site and the allosteric site I, because
both consist of amino acids of different PRS-I units coming
together at the trimer interface.
Mutations that Cause DFN2
The four mutations described for DFN2 can be divided into
two classes: those that foremost affect local structure
(p.A87Tand p.I290T) and those that affect the trimer inter-
face (p.D65N and p.G306R). Ala87 is located in a b sheet inThe Amthe hydrophobic core of the N-terminal domain
(Figure 1L). A change of Ala87 to a more bulky and more
polar threonine side chain will destabilize the surrounding
tightly packed hydrophobic environment. Ile290 is located
at the surface of the PRS-I protein at the edge of the central
b sheet of the C-terminal domain (Figure 1M). Here,
changing to a smaller, butmore polar, threonine side chain
will result in a less-optimal hydrophobic packing, effec-
tively destabilizing this region of the protein.
Asp65 is located in the vicinity of the so-called ﬂag
region of the trimer interface but interacts in the hexamer
interface with Glu62 and Asn64 from another subunit
(Figure 1N). Hence, this change is predicted to lead to an
altered afﬁnity between the different subunits in the hex-
amer. The p.G306R change is located near the center of
the hexamer, at the surface of the protein (Figure 1O).
Modeling shows that the introduction of the much larger
arginine side chain can most likely be accommodated by
PRSP1, because the arginine side chain will be pointing
outward. However, stability of PRSP1 might be affected to
some degree by the introduction of three charged arginine
side chains near the center of the hexamer.
Comparison of the Structural Effect of PRPS1 Mutations
When comparing the protein structural effects of the
PRPS1mutations involved in all four syndromes, themuta-
tions resulting in the mildest symptoms are predicted to
have the least impact on the PRS-I structure (Table 3).
Mutations that result in DFN2 either disturb local stability
of PRS-I or moderately affect interactions in the trimer
interface. Mutations causing PRS-I superactivity mainly
perturb the dimer interface and thereby affect allosteric
sites I and II. Those mutations that result in Arts syndrome
and CMTX5 not only affect the allosteric sites but also
directly impact the ATP-binding site. CMTX5 mutations
appear to affect the stability of the interactions in the
trimer interface, whereas the mutations in Arts syndrome
are predicted to more severely disrupt the overall PRS-I
structure. Additional studies in erythrocytes of patients
or expression of mutant human PRS-I in, for example,
Escherichia coli are needed to conﬁrm these predictions
on the basis of computer-assisted molecular modeling.
Genotype-Phenotype Correlations in PRPS1 Spectrum
Diseases
Aberrations in PRS activity can in principle affect all of the
enzymatic conversions catalyzed by phosphoribosyltrans-
ferase enzymes with PRPP as substrate, i.e., PPAT, HGPRT,
APRT, UMPS, NAPRT, and NAMPT. Consequently, a
number of symptoms that are present in patients with
deﬁciencies in phosphoribosyltransferase enzymes overlap
with those present in patients with PRPS1-related disor-
ders. For example, patients with HGPRT deﬁciency or
Lesch-Nyhan disease (MIM 300322) have purine overpro-
duction similar to PRS-I superactivity and can also have
mental retardation and hypotonia, as found in patients
with Arts syndrome.54 Recurrent infections and earlyerican Journal of Human Genetics 86, 506–518, April 9, 2010 511
Table 3. Predicted Structural Effects of the Known PRSP1 Disease-Causing Mutations
Mutation
Disturbing
Local Structure
Affecting
Dimer Interface
Affecting
Trimer Interface
Disturbing
ATP-Binding Site
Disturbing
Allosteric Site I
Disturbing
Allosteric Site II Neuropathy*
PRS-I superactivity
p.D52H þ  þ  þ  
p.N114S  þ þ  5 5 þ
p.L129I þ     þ þ
p.D183H  þ   5 5 þ
p.A190V þ þ   5 5 þ
p.H193L**  þ   5 5 
p.H193Q  þ   5 5 þ
Arts syndrome
p.Q133P þ þ  þ 5 þ þ
p.L152P þ þ  þ 5 þ þ
CMTX5
p.E43D   þ þ þ  þ
p.M115T   þ þ þ  þ
DFN2
p.D65N   þ    ?
p.A87T þ      ?
p.I290T þ      ?
p.G306R   þ    ?
* 2,5,28,34,35,43.
** This mutation is found in a female patient.death occur in patients with Arts syndrome and were
recorded originally for UMPS deﬁciency (MIM 258900).55
In general, the symptoms in PRPS1-related disorders can
be classiﬁed into three main groups: neurological, hemato-
poietic, and purine overproduction (Table 1). The purine
overproduction symptoms manifest primarily as uric acid
stones, hyperuricemia, and gout and are associated only
with PRS-I superactivity. The mechanisms of the neurolog-
ical and hemapoietic symptoms appear more complex,
and phenotypic variation remains perplexing.
Neurological Symptoms
The major peripheral and central nervous system neurop-
athies in the four PRPS1 spectrum diseases are ataxia,
hypotonia, optic atrophy, and hearing impairment. Re-
markably, neuropathy is observed in patients with gain-
of-function PRS-I superactivity,29–32 despite the predicted
higher levels of purine and pyrimidine nucleotides. This
apparent paradox can be explained by a more labile PRS-I
in case of the superactivity mutations, as predicted by
computer-assisted molecular modeling and supported by
low enzyme activity and low nucleotide levels in erythro-
cytes.31,32,43 Thus, postmitotic cells, including neuronal
cells, appear to have impaired PRS-I activity in all four
syndromes caused by PRPS1 mutations.512 The American Journal of Human Genetics 86, 506–518, April 9, 2The neuropathies could be a result of the reported demy-
elination of neurons. Membrane and myelin synthesis are
dependent on the lipid esters of pyrimidine nucleotides
(e.g., CDP-choline, CDP-neuraminic acid, and CDP-etha-
nolamine).56 In addition, myelin synthesis requires the
methylation cofactor S-adenosylmethionine (SAM) that is
made from methionine and the purine nucleotide adeno-
sine. Accordingly, impaired PRS-I function may cause
a reduction in purine and pyrimidine nucleotides, result-
ing in demyelination.
A second mechanism for the neuropathy, the involve-
ment of impaired pyrimidine nucleotide synthesis in neu-
ropathy, seems to be contradicted by the apparent lack of
neuropathology in UMPS deﬁciency. However, the natural
course of UMPS deﬁciency is not completely known,
because for the past 40 years patients have been success-
fully treated with uridine supplementation,54,55 thus
preventing possible long-term neuropathological conse-
quences, although one UMPS patient in Brisbane on
uridine has a long-term and progressive weakness
(J. McGill, personal communication). In addition, pyrimi-
dine nucleotide salvage, unlike purine salvage, is not
dependent upon PRPP, because pyrimidine nucleosides
(including dietary pyrimidines) are salvaged by kinases.
As a result, themajor pyrimidine nucleotide in erythrocyte,010
uridine diphosphate-glucose, is normal in PRS-I superac-
tivity patients, whereas purine nucleotides are depleted.54
Taken together, however, these observations indicate
that impaired pyrimidine synthesis may not be the pri-
mary cause of the neuropathy observed in PRPS1-related
disorders.
A third model to explain the neuropathy in PRPS1-
related disorders involves the high-energy demand of
neuronal cells. De novo purine synthesis requires seven
ATP molecules for the formation of each mole of purine
nucleotide.12 Therefore, HPRT and APRT normally salvage
purine nucleotides by using PRPP and purine bases as
substrate. These enzymatic conversions need only one
ATP,12 thus conserving much of the energy that might
otherwise be consumed in de novo purine synthesis.
Ninety percent of the free purine bases in humans are
recycled, stressing the importance of purine base salvage.57
Impaired PRS-I function reduces PRPP levels, affecting
both purine nucleotide de novo synthesis and salvage.
Because PPAT is the rate-limiting enzyme of de novo
purine nucleotide synthesis, speciﬁc upregulation of
PPAT may be expected in patients with loss-of-function
mutations in PRS-I to compensate for the reduced purine
nucleotide levels. Indeed, preliminary experimental results
indicate that in ﬁbroblasts from Arts syndrome patients,
mRNA transcript levels of PPAT (MIM 172450) are signiﬁ-
cantly increased by 1.6-fold (p ¼ 0.028 with a two-sided
Student’s t test; A.P.M.d.B. and H.v.B., unpublished data).
This would then result in a higher energy consumption
for purine nucleotide synthesis in patients with PRS-I
loss-of-function mutations, because PPAT upregulation
commits the cell to energy-demanding de novo synthesis
rather than to the energy-saving salvage pathway. In
addition, the brain appears to maintain its major purine
nucleotides largely via HGPRT salvage of hypoxanthine.
Free adenosine, guanosine, or adenine levels are usually
low, less than 1 mM.58,59 When HGPRT deﬁciency in Lesch
Nyhan syndrome cuts purine salvage, the result is a severe
neuropathy similar to that in patients with CMTX5 and
Arts syndrome.54 Furthermore, the lack of any neurol-
ogical phenotype in patients with APRT deﬁciency60
supports the assumption that salvage of adenine is not
essential for ATP synthesis in the brain. Dependence of
ATP salvage on HGPRT only would render neuronal cells
even more sensitive to a reduction in PRPP levels caused
by a loss of PRS-I activity compared to other cell types. In
this energy-depletion model, gain-of-function PRPS1
mutations would simply result in the use of more ATP
than normal through stimulation of de novo synthesis of
purine nucleotides. This hypothesis is supported by the
high degree of PRS-I activity regulation in the brain, at least
on an RNA level, by miR-376.
A fourth model for the PRS-I neuropathy proposes the
involvement of reduced GTP levels in neurons.61 GTP is
essential for the activation of the Rho family of small
(20–30 kDa) GTPases,62 of which the major function in
neurons is to regulate the assembly and organization ofThe Amthe actin cytoskeleton.63 In the nervous system, these
GTPases are essential regulators of neuronal growth cone
motility, axonal migration, and dendritic spine morpho-
genesis.64–66 Mutations in several regulators or effectors
of Rho GTPases, such as ARHGEF6 (MIM 300267),
OPHN1 (MIM 300127), PAK3 (MIM 300142), FGD1 (MIM
300546), and GDI1 (MIM 300104), result in mental retar-
dation.67 Patients with HGPRT deﬁciency have low GTP
levels in erythrocytes and ﬁbroblasts61,68 and a neuronal
phenotype that can include mental retardation and that
in general resembles that of the PRPS1-related disorders.54
Speciﬁcally, HGPRT deﬁciency is associated with abnormal
dopamine function that is thought to delay neuronal
development,69–71 and maintenance of dopamine levels
is totally dependent upon GTP72 through the ﬁrst step in
dopamine synthesis catalyzed by GTP cyclohydrolase I. In-
herited deﬁciency of GTP cyclohydrolase I (MIM 233910)
results in a severe neurological syndrome similar to both
HGPRT deﬁciency and PRPS1-related disorders.2,5,26,31,73
Because erythrocytes of patients with PRS-I superactivity
also contain low levels of GTP,31 reduced GTP levels might
play a role in the neurological dysfunction in these
patients as well. Supporting the concept of a GTP-related
neurological disease group, a number of other genes
involved in the Charcot-Marie-Tooth spectrum of diseases
are also GTP dependent, for example, ARGHEF10 (MIM
608136), DNM2 (MIM 602378), FGD4 (MIM 611104),
MFN2 (MIM 608507), and RAB7 (MIM 602298).74,75
Thus, depletion in GTP levels, affecting central neurolog-
ical functions such as GTPases and dopamine synthesis,
may explain an important part of the neurological pheno-
type of Arts syndrome and CMTX5.
Finally, the occurrence of PRPS1-related neuropathymay
relate to the loss of pyridine nucleotide synthesis, for
example, the energy cofactors NAD and NADP. In partic-
ular, NAD is required for oxidoreductive cell processes
and is essential for mitochondrial oxidative phosphoryla-
tion and ATP generation. Production of NAD is PRPP
dependent, and these pyridine nucleotides have been
shown to be severely reduced in erythrocytes of patients
with PRS-I superactivity and a severe neuropathy.31 Further
studies of the status of pyridine nucleotides in patients
with Arts syndrome or CMTX5 are required to establish
mitochondrial functionality, especially in neuronal cells.
Hematopoietic Symptoms
Arts syndrome differs from DFN2, CMTX5, and PRS-I
superactivity in that Arts syndrome patients are liable to
severe infections of the respiratory tract that often result
in early death.4 A role for PRS-I in hematopoietic differen-
tiation is supported by the high expression of PRPS1 in
erythrocytes, B- and T-lymphocytes, and natural killer cells
(BioGPS),76 as well as normal lymphatic tissues, such as
lymph, spleen, and thymus (UniGene expression proﬁle).
In Arts syndrome patients, the total number of B- and
T-lymphocytes and natural killer cells was normal, but
IgA was found repeatedly in the low-normal range.4 Thiserican Journal of Human Genetics 86, 506–518, April 9, 2010 513
Figure 2. Simplified Overview of the Purine Metabolism
Pathway
The scheme is derived from KEGG Pathways hsa00230 (purine
metabolism) and hsa00240 (pyrimidine metabolism).12 Indicated
in red is the alternative pathway to replenish purine nucleotides
via SAM. Enzymes central in this review are highlighted by blue
boxes. PRS-I is printed in bold. Boxes show the essential role of
PRPP in the purine metabolism. Dashed arrows indicate multiple
intermediate steps that are not shown. PRPP is also used for the
de novo synthesis of pyrimidines, as indicated by the arrow to
UMP, the central intermediate in pyrimidine pathway. In addition,
PRPP is essential for pyridine nucleotide (NAD/NADP) synthesis
(not shown).may point to a defect in the differentiation of B-lympho-
cytes to plasma cells and memory cells, because IgA plays
a crucial role in the ﬁrst line of immune defense at mucosal
surfaces, such as the respiratory and urinary tract.77 A
speciﬁc role for PRS-I in hematopoiesis is further supported
by the direct association of PRS-I withp300,78 a histone ace-
tyltransferase that is essential for hematopoietic differenti-
ation, as shown in murine embryonic stem cells lacking
p300 expression.79 In humans, heterozygous mutations
in p300 cause an atypical form of the autosomal-dominant
inherited Rubinstein-Taybi syndrome,80,81 which is charac-
terized by mental retardation, typical dysmorphic features,
and recurrent infections in the respiratory or urinary tract.
Recurrent infections are also a symptom of one pyrimi-
dine disorder, UMPS deﬁciency,82 and two purine disor-
ders, purine nucleoside phosphorylase (PNP) deﬁciency
(MIM 164050)83 and adenosine deaminase (ADA) deﬁ-
ciency (MIM 102700).84 Patients with PNP deﬁciency
suffer from severe neuropathy accompanied by a late-onset
T-cell immunodeﬁciency. Patients with ADA deﬁciency
present neonatally with severe combined T- and B-cell deﬁ-
ciency. In both diseases, the impaired immune system is
proposed to result from reduced nucleic acid synthesis
caused by inhibition of ribonucleotide reductase through
abnormal accumulation of the deoxynucleotides deoxy514 The American Journal of Human Genetics 86, 506–518, April 9, 2GTP or deoxyATP,84–86 rather than from nucleotide deple-
tion. Furthermore, UMPS deﬁciency would also result in
impaired nucleic acid synthesis. However, in contrast to
patients with UMPS deﬁciency, patients with Arts syn-
drome are not anemic (W.F.A., unpublished data). In
summary, we propose that the immune deﬁciency in
patients with Arts syndrome is predominantly caused by
impaired nucleic acid synthesis in hematopoietic cells, re-
sulting in ﬂawed hematopoietic differentiation.
Inter- and Intrafamilial Phenotypic Variability
The phenotype among patients with PRS-I superactivity
and Arts syndrome varies considerably.4,26 This pheno-
typic variation could be the result of redundancy in the
production of PRPP among the three PRS isoforms, en-
coded by PRPS1, PRPS2, and PRPS1L1. However, PRPS2
transcript levels were not found to be elevated to compen-
sate for PRS-I deﬁciency in patients with Arts syndrome.5
Second, the clinical variability may result from polymor-
phisms in genes encoding regulators of PRS-I synthesis,
such as miR-376. However, no miR-376 sequence variants
have been identiﬁed in the original Arts syndrome kindred
(W. Chen, personal communication). Third, differences in
PPAT expression levels between individuals might result in
an attenuation of the phenotype. This last possibility is yet
to be pursued.
SAM Treatment of Patients with PRS-I Deﬁciency
Dietary pyrimidine nucleotides are readily absorbed by the
gut55 so that symptoms caused by impaired de novo
pyrimidine synthesis can be moderated by the addition
of dietary pyrimidines, such as uridine. In contrast, dietary
purines are usually oxidized to uric acid by the gut rather
than being absorbed into the body.87 However, unlike
most purines, SAM can cross both the gut and the blood-
brain barrier and has been successfully used in the treat-
ment of depression and osteoarthritis.88 Importantly, side
effects are few. In addition, SAM is also a source of methi-
onine, which could overcome a possible deﬁciency of
methylation-dependent processes, including myelin
synthesis. Theoretically, SAM can replenish both ATP and
GTP independently of PRPP (Figure 2). Methyltransferases
convert SAM into S-adenosylhomocysteine. Subsequently,
S-adenosylhomocysteine hydrolase (AHCY) catalyzes the
conversion of S-adenosylhomocysteine to mainly adeno-
sine, although adenine can be formed by AHCY, or SAM
can be converted directly to adenine, via the polyamine
pathway.89,90 Adenine can subsequently be turned into
AMP by APRT, which still requires PRPP as substrate. Alter-
natively, adenosine can be salvaged to form purine nucle-
otides via ubiquitous adenosine kinase, which does not
require PRPP as cofactor. AMP can then be converted to
ATP, or via AMP deaminase to IMP, which can then be
used to synthesize GTP.
AHCY is ubiquitously and highly expressed through-
out the human body (BioGPS;76 UniGene expression
proﬁle). Notably, the phenotype of a patient with two010
complementary mutations that result in AHCY deﬁciency
(MIM 180960) resembles that of PRPS1-related disorders
(Table 1).91 The patient presented with delayed psycho-
motor development accompanied by hypotonia and a
loss of deep tendon reﬂexes that is likely the result of the
reported abnormal myelination. However, the patient
also exhibited symptoms that are not present in patients
with PRPS1-related disorders, namely progressive myop-
athy and mild chronic hepatitis. This difference may be
explained by the low PRPS1 expression levels in muscle
and liver. Taken together, the phenotype suggests that
AHCY activity is particularly important for energy-
requiring tissues, such as the nervous system, muscle,
and liver. This may be because AHCY plays an important
role in ATP provision, independent of PRS-I or PRS-II, by
recycling adenosine.
Recently, a patient with HPRT deﬁciency was shown to
clearly beneﬁt neurologically from SAM administration
without untoward side effects,92 which supports the
hypothesis that brain purine nucleotide levels can be
elevated and clinical symptoms alleviated by SAM therapy.
We have begun oral supplementation with SAM at a dose
of 20 mg/kg/day in the two affected boys with Arts
syndrome from the Australian family (J.C., unpublished
data; trial is approved by the Ethics and Drug Committees
of the Children’s Hospital at Westmead, Sydney, Australia).
They appear to have beneﬁted from this therapy. Prior to
commencing SAM treatment, the older of the two boys
spent a total of 180 days over a time span of 84 months
in the hospital, including two admissions that required
mechanical ventilation in a pediatric intensive care unit.
In the 33 months since the onset of the treatment, he
only had one 5 day admission to a general ward. His
younger brother was admitted to the hospital for 82 days
in the 84-month period prior to commencement of the
therapy but has required no admissions over the last
33 months since starting SAM treatment. In addition, the
progression of other symptoms like the ataxia and hearing
impairment appear to have been stabilized. Until now,
there has been no apparent need for supplementation
with uridine to compensate for theoretically reduced de
novo synthesis of pyrimidine nucleotides.
Conclusions
Both gain-of-function and loss-of-function mutations
have now been identiﬁed in PRPS1. Gain-of-function
mutations result primarily in a loss of feedback regulation
and hence PRS-I ‘‘superactivity,’’ as assayed in ﬁbroblasts
and lymphoblasts. However, these mutations also result
in a loss of activity in postmitotic cells, such as erythro-
cytes, and perhaps neuronal cells.26 Predictions of the
effect of the gain-of-function mutations on the structure
of the PRS-I protein by computer-assisted molecular
modeling suggest that this loss of activity may be caused
by a lower stability of the PRS hexamer that surpasses the
loss of feedback regulation in these cells. Loss-of-function
mutations cause DFN2, CMTX5, and Arts syndrome.2,5,6The AmDFN2 and CMTX5 seem to be milder forms of PRS-I
deﬁciency, because only hearing loss and/or peripheral
neuropathy are reported. In contrast, patients with Arts
syndrome have neuropathy of the central nervous system
as well as a defective immune system. Taken together, the
clinical and molecular ﬁndings suggest that the four PRPS1
disorders discovered to date are part of the same disease
spectrum. Additional neurophysiological investigations
may reveal further phenotypical overlap or differences
between the PRPS1 spectrum diseases. In general, the
neurological phenotype in PRPS1 disorders may result
primarily from GTP depletion and possibly reduced levels
of other nucleotides, including ATP. We propose that the
immune deﬁciency in patients with Arts syndrome is
predominantly caused by impaired nucleic acid synthesis
in hematopoietic cells, resulting in ﬂawed hematopoietic
differentiation. Because PRPS1 loss-of-function mutations
in Arts syndrome give rise to a very severe disorder with
early death, deletions of the gene may be embryonically
lethal.
SAM supplementation in the diet may alleviate some of
the symptoms of the patients with PRPS1 loss-of-function
mutations by replenishing purine nucleotides indepen-
dent of PRPP production. An open-label clinical trial in
the two affected Australian brothers is currently under
way and appears to have improved the health of the
patients, although it is too early to draw signiﬁcant conclu-
sions. Patients with DFN2 and CMTX5 and mildly affected
carrier females from the original Arts syndrome may also
beneﬁt from SAM supplementation in their diet.Acknowledgments
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